Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant Chemotherapy

Journal of Clinical Medicine

Tania Lobato¹  Vicenç Ruiz de Porras¹  Anna Martinez-Cardús¹  Lidia Estudillo²  Mireia Jordà³  Helena Rodriguez³  Juan Carlos Pardo⁴  Olatz Etxaniz⁴  Albert Font⁴  Daniel Castellano⁵  Enrique Grande⁶  Miquel A. Climent⁷  Tamara Sanhueza⁸  Cristina Carrato⁸ 

[1] Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), 08916 Badalona, Spain;Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), CIBERONC, 28029 Madrid, Spain;Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain;Medical Oncology Department, Catalan Institute of Oncology, Ctra. Can Ruti- Camí de les Escoles s/n, 08916 Badalona, Spain;Medical Oncology Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain;Medical Oncology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain;Medical Oncology Department, Instituto Valenciano de Oncologia, 46009 Valencia, Spain;Pathology Department, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain;

关键词: CD36;    MIBC;    bladder cancer;    adjuvant chemotherapy;    prognostic biomarker;    lipid metabolism;   

DOI  :  10.3390/jcm11030497

来源: DOAJ

【 摘 要 】

Neoadjuvant chemotherapy followed by a cystectomy is the standard treatment in muscle-invasive bladder cancer (MIBC). However, the role of chemotherapy in the adjuvant setting remains controversial, and therefore new prognostic and predictive biomarkers are needed to improve the selection of MIBC patients. While lipid metabolism has been related to several biological processes in many tumours, including bladder cancer, no metabolic biomarkers have been identified as prognostic in routine clinical practice. In this multicentre, retrospective study of 198 patients treated with cystectomy followed by platinum-based adjuvant chemotherapy, we analysed the immunohistochemical expression of CD36 and correlated our findings with clinicopathological characteristics and survival. CD36 immunostaining was positive in 30 patients (15%) and associated with more advanced pathologic stages (pT3b-T4; p = 0.015). Moreover, a trend toward lymph node involvement in CD36-positive tumours, especially in earlier disease stages (pT1-T3; p = 0.101), was also observed. Among patients with tumour progression during the first 12 months after cystectomy, disease-free survival was shorter in CD36-positive tumours than in those CD36-negative (6.51 months (95% CI 5.05–7.96) vs. 8.74 months (95% CI 8.16–9.32); p = 0.049). Our results suggest an association between CD36 immunopositivity and more aggressive features of MIBC and lead us to suggest that CD36 could well be a useful prognostic marker in MIBC.

【 授权许可】

Unknown